Publicado 26/03/2020 13:09:00 +01:00CET

COMUNICADO: Immunexpress recibe el marcado CE y firma una alianza de comercialización para SeptiCyte® RAPID (2)

Sigue a Immunexpress en Twitter [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=854844606&u=...] y LinkedIn [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=3064814854&u...].

*Immunexpress tiene licencia para usar la marca comercial Idylla(TM) de Biocartis NV.

Contacto para los medios de comunicación: Maggie BellerRusso Partners, LLC+1(646) 942-5631Maggie.beller@russopartnersllc.com[mailto:Maggie.beller@russopartnersllc.com]

(1)Zhou, F., et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3 [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=1684565204&u...(20)30566-3%26a%3Dhttps%253A%252F%252Fdoi.org%252F10.1016%252FS0140-6736(20)30566-3&a=https%3A%2F%2Fdoi.org%2F10.1016%2FS0140-6736(20)30566-3]

Logo -- https://mma.prnewswire.com/media/1033289/Immunexpress_Inc.jp... [https://c212.net/c/link/?t=0&l=es&o=2761461-1&h=3177164429&u...]

Sitio Web: http://www.immunexpress.com/

Contador